New drug VTX3232 shows promise for early Parkinson's safety
NCT ID NCT06556173
First seen Apr 23, 2026 · Last updated May 11, 2026 · Updated 1 time
Summary
This study tested whether a new drug called VTX3232 is safe for people with early-stage Parkinson's disease. Eleven participants took the drug for 28 days and were monitored for side effects. The goal was to see if the drug is well-tolerated and how it moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Site #840001
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.